Sugi Predict

Sugi Predict / Compounds / SCHEMBL2225468

SCHEMBL2225468

SCHEMBL2225468

Brc1nc(-c2ccccc2)cs1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 4/20 0.63
▸ RAB9A P51151 6/20 0.59
▸ KMT2A Q03164 5/20 0.59
▸ MEN1 O00255 4/20 0.59
▸ SMN1; SMN2 Q16637 4/20 0.59
▸ KDM4E B2RXH2 3/20 0.59
▸ MAPT P10636 3/20 0.59
▸ NPC1 O15118 3/20 0.59
▸ LMNA P02545 1/20 0.59
▸ NFKB1 P19838 1/20 0.59
▸ NFKB2 Q00653 1/20 0.59
▸ RELA Q04206 1/20 0.59
▸ CYP3A4 P08684 1/20 0.59
▸ AR P10275 4/20 0.55
▸ GFER P55789 1/20 0.53
▸ LOXL2 Q9Y4K0 1/20 0.52
▸ SREBF2 Q12772 1/20 0.52
▸ TAAR1 Q96RJ0 1/20 0.50
▸ ATP4A P20648 1/20 0.50
▸ ATP4B P51164 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19196250 0.86 ALDH1A1 (0.53) ALDH1A1RAB9AKMT2AMEN1SMN1; SMN2
SCHEMBL3174725 0.82 RAB9A (0.68) ALDH1A1RAB9AKMT2AMEN1SMN1; SMN2
SCHEMBL4076416 0.79 ALDH1A1 (0.74) ALDH1A1RAB9AKMT2AMEN1SMN1; SMN2
SCHEMBL3823252 0.78 RAB9A (0.58) ALDH1A1RAB9AKMT2AMEN1SMN1; SMN2
SCHEMBL533699 0.78 RAB9A (0.44) ALDH1A1RAB9AKMT2AMEN1SMN1; SMN2
SCHEMBL3761118 0.78 RAB9A (0.66) ALDH1A1RAB9AKMT2AMEN1SMN1; SMN2
SCHEMBL28679988 0.78 LTA4H (0.66) ALDH1A1RAB9AKMT2AMEN1SMN1; SMN2
SCHEMBL1774137 0.78 RAB9A (0.58) ALDH1A1RAB9AKMT2AMEN1SMN1; SMN2
SCHEMBL23924237 0.78 CYP19A1 (0.69) ALDH1A1RAB9AKMT2AMEN1SMN1; SMN2
SCHEMBL2781370 0.77 KDM4E (0.85) ALDH1A1RAB9AKMT2AMEN1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 135 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4725942-A1 COMPOUNDS ACTIVE ON CYCLIN D1 PATHWAY AND THEIR USE Sibylla Biotech S.p.A. (IT) 2026-04-15 — — EP disclosed
EP-4558494-A1 1,3,4-OXADIAZOLE DERIVATIVES AS SELECTIVE HISTONE DEACETYLASE 6 INHIBITORS ITALFARMACO S.p.A. (IT) 2025-05-28 — — EP disclosed
CN-119562949-A 1,3, 4-Oxadiazole derivatives as selective histone deacetylase 6 inhibitors 意大发马克股份公司 2025-03-04 — — CN disclosed
US-12145927-B2 Inhibitors of indoleamine 2,3-dioxygenase and methods of their use BRISTOL-MYERS SQUIBB COMPANY (US) 2024-11-19 — — US disclosed
EP-3800186-B1 CYANOPYRROLIDINES AS DUB INHIBITORS FOR THE TREATMENT OF CANCER MISSION THERAPEUTICS LTD (GB) 2024-10-02 — — EP disclosed
CN-114025847-B Compounds and compositions as modulators of TLR signaling 神经孔疗法股份有限公司 2024-05-24 — — CN disclosed
WO-2024017897-A1 1,3,4-OXADIAZOLE DERIVATIVES AS SELECTIVE HISTONE DEACETYLASE 6 INHIBITORS ITALFARMACO S.P.A. (IT) 2024-01-25 — — WO disclosed
WO-2024017897-A1 1,3,4-OXADIAZOLE DERIVATIVES AS SELECTIVE HISTONE DEACETYLASE 6 INHIBITORS ITALFARMACO S.P.A. (IT) 2024-01-25 — — WO disclosed
WO-2023217879-A1 PYRROLIDIONE DERIVATIVES AS INHIBITORS OF NF KAPPA B INDUCING KINASE JANSSEN PHARMACEUTICA NV (BE) 2023-11-16 — — WO disclosed
EP-3054936-B1 4-((2-HYDROXY-3-METHOXYBENZYL)AMINO) BENZENESULFONAMIDE DERIVATIVES AS 12-LIPOXYGENASE INHIBITORS EASTERN VIRGINIA MEDICAL SCHOOL (US) 2023-10-18 — — EP disclosed
US-7214801-B2 Condensation reagents and a process for their preparation LANXESS DEUTSCHLAND GMBH (DE) 2007-05-08 — — US disclosed
US-7214801-B2 Condensation reagents and a process for their preparation LANXESS DEUTSCHLAND GMBH (DE) 2007-05-08 — — US disclosed
US-7214801-B2 Condensation reagents and a process for their preparation LANXESS DEUTSCHLAND GMBH (DE) 2007-05-08 — — US disclosed
CN-1310893-C Condensation reagent and its preparation method BAYER AG (DE) 2007-04-18 — — CN disclosed
US-7064216-B2 Condensation reagents and a process for their preparation BAYER AKTIENGESELLSCHAFT (DE) 2006-06-20 — — US disclosed
US-20050267174-A1 Condensation reagents and a process for their preparation RUDOLPH JOACHIM 2005-12-01 — — US disclosed
US-20020156287-A1 Condensation reagents and a process for their preparation LANXESS DEUTSCHLAND GMBH (DE) 2002-10-24 — — US disclosed
CN-1365975-A Condensation reagent and its preparation method BAYER AG (DE) 2002-08-28 — — CN disclosed
EP-1216997-A2 2-bromo/chloro-thiazolium salts and their use as condensation agents BAYER AG (DE) 2002-06-26 — — EP disclosed
US-4476128-A ANTIARTHRITIC AGENTS ANTIBODY INHIBITORS MITSUITOATSU CHEMICALS, INC. (JP) 1984-10-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050267174-A1 Condensation reagents and a process for their preparation C9, QPCT, RCC1 ALDH1A1 4387/4885RAB9A 3438/4885KMT2A 3870/4885
US-12145927-B2 Inhibitors of indoleamine 2,3-dioxygenase and methods of their use IDO1, IDO2, INMT ALDH1A1 508/4885RAB9A 4504/4885KMT2A 533/4885
US-20020156287-A1 Condensation reagents and a process for their preparation RCC1, C9, CCNT1 ALDH1A1 3798/4885RAB9A 3092/4885KMT2A 3933/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.